Clara Rodríguez Fernández, Author at Labiotech.eu

About

Traveler, musician, food enthusiast and book worm. Always on the hunt for interesting facts and news.

Articles by Clara Rodríguez Fernández

News and Trends 12 Oct 2016

Will Aprea live up to the Hype of its €46M fundraising?

Aprea raised a huge €46M for a first-in-class drug that targets the deadliest form of ovarian cancer. The company just started Phase II trials after positive results from Phase I. But will it be able to outperform all its competitors? Aprea is a spin-out company from the Karolinska Development, the portfolio company of the Institute, in Sweden. It became […]

October 12, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 11 Oct 2016

World Mental Health Day: How is Biotech Helping the Cause?

Biotech is one of the main forces driving the development of effective therapies to treat neurological and mental disorders. For World Mental Health Day yesterday, we want to share with you some of the latest technologies that address these conditions. Yesterday, October 10th, was World Mental Health Day: it is dedicated to raising awareness of neurological and mental disorders […]

October 11, 2016 - 4 minutesmins - By Clara Rodríguez Fernández

News and Trends 8 Oct 2016

Microbial Donuts at the Vienna Design Week, fancy a bite? Here’s the Recipe!

This week’s bioartist has a very sweet exhibition at the Vienna Design Week. Taylor Caputo has traveled from the other side of the pond to showcase her current project: custom donuts engineered with synthetic biology. Six talented artists are showing their work at Possible Tomorrows, an exhibition at the Vienna Design Week that combines art with Biotech and SynBio to experiment […]

October 8, 2016 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 7 Oct 2016

Will SynBio replace the French Wine Industry?

Ava Winery is creating cheap, sustainable and customizable wine without grapes, yeast or fermentation. The company plans to commercialize its first product in the coming months, will they be able to steal customers from the most famous French wine companies? Ava Winery claims that 90% of tasters cannot tell its prototype apart from traditional wine. The […]

October 7, 2016 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 6 Oct 2016

New UK Hero Will Fight Against Non-Small Cell Lung Cancer

Achilles Therapeutics was born yesterday in the UK with a €15M funding round. The company will focus on the development of personalized neo-antigentherapies for non-small lung cancer. The newborn Achilles Therapeutics made its debut yesterday with a splashy fundraising round and a licensing agreement. The startup has exclusive rights to develop and commercialize any neo-antigen technology that […]

October 6, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 5 Oct 2016

€365M deal for a Danish ‘DNA barcode’ Drug Screening Platform

The giant Amgen has offered Nuevolution €365M to develop oncology and neuroscience drugs. The small Danish Biotech claims to count with an unprecedented drug discovery platform that can screen billions of compounds way faster and at a lower cost than the big players. Despite its small size, Nuevolution is experienced in collaborating with big Pharma like Merck, Novartis, […]

October 5, 2016 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 5 Oct 2016

New Psoriasis Antibody Therapy puts pressure on Best-Seller drug Humira

New results from a Phase III trial show that guselkumab, an antibody therapy for the autoimmune disease plaque psoriasis, is performing better than the number one best-seller drug Humira (adalimumab) from AbbVie. The new drug is expected to be commercially available as early as 2018. Since MorphoSys licensed guselkumab to Janssen Biotech, in 2007, the drug has been performing […]

October 5, 2016 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 4 Oct 2016

One Step Closer to an HIV Cure That Can Eliminate the Latent Virus

HIV has completely disappeared from the blood of a patient in clinical trials. The new HIV treatment that can target the virus even in its dormant state by activating latent infected cells and could possibly become the first HIV cure available. These initial results show that the new therapy, developed in the UK, may be effective in curing HIV. One of 50 […]

October 4, 2016 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 3 Oct 2016

Researchers Find New Weak Spots to Develop an HIV Cure

Last week we published a thorough review on current approaches for an HIV cure, which may be available as soon as 2020. Academia has come up with two additional strategies that could make a huge difference in the study of HIV. HIV affects 36.7 million people in the world and caused 1.1 million deaths last year. Plenty of resources […]

October 3, 2016 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 1 Oct 2016

This Belgian Bioartist is deconstructing Chicken Evolution

Koen Vanmechelen is an artist that works in the intersection of art and research. His art focuses on exploring biocultural diversity… using chickens! Koen Vanmechelen‘s core artistic work is the Cosmopolitan Chicken Project (CCP), in which the artist cross-breeds chickens from all around the world. The aim: to create the ultimate chicken that will combine genes from […]

October 1, 2016 - 3 minutesmins - By Clara Rodríguez Fernández

Screenshot 2016 09 29 at 4.53.52 PM e1475160985987

News and Trends 30 Sep 2016

Tailored Cancer Vaccines? NousCom is working on it!

We aren’t leaving Switzerland yet! We took a scenic train to Basel in order to meet nousCom, a very young biotech developing cancer vaccines. City: Basel, Switzerland Founded: 2015 Employees: unknown Financial Data: €12M raised in series A Mission: NousCom is a Biotech that develops next generation cancer vaccines with patient- and tumor-specific antigens. Their vaccines combine viruses […]

September 30, 2016 - 1 minutemin - By Clara Rodríguez Fernández

News and Trends 30 Sep 2016

Interview: GeNeuro’s CFO explains its Unique Multiple Sclerosis Treatment

GeNeuro is developing a unique treatment for multiple sclerosis. We interviewed Miguel Payro, the company’s CFO, who explained its advantageous position against big pharma. GeNeuro raised €33M in its Euronext IPO in April and is currently competing against giants like Novartis and Biogen. Despite 2016’s dubious honor as “the worst year for IPO in 20 years”, this Switzerland-based company has managed to go […]

September 30, 2016 - 1 minutemin - By Clara Rodríguez Fernández

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us